Women with hemophilia: inherited differences in laboratory and registry records
Women with hemophilia appear in genetic experiments, medical records and national datasets, including women with inherited forms of the disease. Hemophilia A involves the F8 gene and clotting factor VIII; hemophilia B involves F9 and factor IX. MedlinePlus Genetics explains why their usual association with males does not exclude females: one altered gene copy can sometimes be sufficient when the X chromosome carrying the functioning copy is preferentially inactivated. The distinction between carrying a variant and having bleeding symptoms therefore requires more than counting the two X chromosomes usually present in female cells. A separate inherited condition, factor XI deficiency, is also called hemophilia C. MedlinePlus classifies its severe form as autosomal recessive, an inheritance pattern with equal likelihood of affecting male and female children.
X-inactivation begins early in embryonic development. Normally, different cells inactivate different copies, producing a mixture across the body. Sometimes the balance is uneven, leaving one X chromosome active in more cells than the other. MedlinePlus calls this skewed X-inactivation. Its description separates inherited hemophilia from acquired hemophilia, in which antibodies interfere with factor VIII rather than an inherited variant causing the problem. These are different routes to impaired clotting. The existence of the acquired form does not explain away inherited disease in females, because the genetic mechanism can itself produce a symptomatic condition.
A 2014 PLOS ONE investigation made that mechanism observable in actual samples. Filipe Brum Machado and colleagues developed a method for distinguishing active and inactive X chromosomes through methylation marks near the RP2 gene. They compared its results with an established assay based on the androgen receptor gene. Among their subjects were four confirmed female carriers of hemophilia A variants. Two had no symptoms and random X-inactivation patterns; the other two had severe hemophilia A and extremely skewed patterns. The latter carried different kinds of F8 changes, including a missense variant and a frameshift variant.
The laboratory project was primarily an investigation of how to measure X-inactivation, rather than a population survey of women with hemophilia. Its value was the connection between a molecular pattern and contrasting clinical histories in the people examined. The new assay's results closely agreed with the established comparison method. Both genetic carrier status and whether a person had severe bleeding disease were therefore present in the experimental design. Four selected cases could illustrate those distinctions, but could not determine how frequently severe disease occurs among all females carrying an F8 variant.
Clinical records supplied another scale of observation. A study published in 2023 compared insurance claims from females diagnosed as hemophilia A carriers with claims from matched females without that diagnosis. Shan Xing and colleagues used commercial and Medicaid databases covering 2016 through September 2019. After matching, the carrier groups contained 121 commercially insured patients and 55 Medicaid patients, with two comparison patients for each carrier. Matching included social and demographic characteristics, pregnancy status and insurance type. This design examined recorded events and healthcare use in existing administrative data, rather than assigning participants an experimental treatment.
Both insurance groups showed more billed bleeding events among carriers. Annualized rates were 0.49 versus 0.33 in the commercial comparison and 0.50 versus 0.29 in Medicaid. The investigators also reported more spontaneous bleeding and higher healthcare costs in the carrier groups. These were observations about diagnosed, insured populations, not estimates for every woman carrying an altered gene. The publication disclosed funding from Takeda and the sponsor's participation in the research. Its administrative perspective complemented genetic work by documenting consequences registered through healthcare encounters, while remaining dependent on the diagnoses and events that generated claims.
A 2025 investigation used the American Thrombosis and Hemostasis Network dataset to examine carriers across the lifespan. Neeraja Swaminathan and colleagues analyzed 2010–2020 records for 3,663 carriers: 2,728 associated with hemophilia A and 935 with hemophilia B. They divided the population into childhood, reproductive-age and older groups. Joint bleeding appeared across the age groups, and factor VIII activity in hemophilia A carriers increased with age. The authors also found increased recorded use of hemostatic therapies over the study period. Their discussion acknowledged missing data and possible underreporting, limitations inherent in drawing conclusions from registry entries.
The institutional diagrams used to explain inheritance concern a different measurement again. NHLBI illustrates a carrier mother's potential transmission to daughters and sons and an affected father's transmission to daughters. In its example with an unaffected father, each daughter has a 50% chance of inheriting the mother's hemophilia gene. In the illustration with an affected father, every daughter inherits his hemophilia gene. Those diagrams track the route of a gene through a family. They do not measure symptoms in any particular daughter. NHLBI also distinguishes genetic causes of bleeding disorders from conditions that interfere with clotting factors later in life. For women with hemophilia, the combined research record contains all of these dimensions: inheritance, X-chromosome activity, observed bleeding and recorded healthcare use. No single family diagram or laboratory value encompasses the differences documented across them.
- MedlinePlus Genetics, Hemophilia: F8, F9 and X-inactivation — medlineplus.gov
- Machado and colleagues, 5meCpG Epigenetic Marks and X-Chromosome Inactivation, PLOS ONE, 2014 — journals.plos.org
- Xing and colleagues, Hemophilia A carriers and noncarriers: US insurance claims comparison, 2023 — pmc.ncbi.nlm.nih.gov
- Swaminathan and colleagues, Hemophilia carriers in the ATHN dataset, 2025 — pmc.ncbi.nlm.nih.gov
- NHLBI, Bleeding Disorders: Causes and Risk Factors, 2023 — www.nhlbi.nih.gov
- MedlinePlus Genetics, Factor XI deficiency: hemophilia C and autosomal inheritance — medlineplus.gov
- MedlinePlus Medical Encyclopedia, Genetics: autosomal recessive inheritance — medlineplus.gov